%0 Journal Article
%A Díaz-Beyá, M
%A Brunet, S
%A Nomdedéu, J
%A Cordeiro, A
%A Tormo, M
%A Escoda, L
%A Ribera, J M
%A Arnán, M
%A Heras, I
%A Gallardo, D
%A Bargay, J
%A Queipo de Llano, M P
%A Salamero, O
%A Martí, J M
%A Sampol, A
%A Pedro, C
%A Hoyos, M
%A Pratcorona, M
%A Castellano, J J
%A Nomdedeu, M
%A Risueño, R M
%A Sierra, J
%A Monzó, M
%A Navarro, A
%A Esteve, J
%T The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
%D 2015
%U http://hdl.handle.net/10668/2049
%X Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
%K MicroARNs
%K Mitoxantrona
%K Citarabina
%K Etopósido
%K Idarrubicina
%K Leucemia mieloide aguda
%K Citogenética
%K Expresión génica
%K Humanos
%K Pronóstico
%K Análisis citogenético
%K Incidencia
%K Cariotipo
%K Análisis multivariante
%K Recurrencia
%K Anciano
%~